Eying NASH, Glympse Raises $22M to Test Disease Detection Nanotech
Summary
As Glympse prepares to test its disease detection approach in a serious liver disorder, the startup has raised $22 million in financing.Glympse has developed bioengineered nanoparticles that circulate through the body, detect disease, and report their findings through a signal read by testing the patient’s urine.One of the challenges of treating NASH is that patients who have the disease typically show few symptoms and a tissue sample is required to confirm the diagnosis, according to Merck Manuals .Earlier investors GreatPoint Ventures, Heritage Provider Network, and Rivas Capital also contributed to the financing.Glympse had previously raised $6.6 million in a 2015 seed capital led by Kiran Mazumdar-Shaw at Biocon India, and Theresia Gouw at Aspect Ventures.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
